{"id":453631,"date":"2021-03-09T08:08:11","date_gmt":"2021-03-09T13:08:11","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=453631"},"modified":"2021-03-09T08:08:11","modified_gmt":"2021-03-09T13:08:11","slug":"tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/","title":{"rendered":"TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, March  09, 2021  (GLOBE NEWSWIRE) &#8212; TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 31<sup>st<\/sup> Annual Healthcare Conference on March 16, 2021\u00a0at 3:10pm Eastern Time.<\/p>\n<p align=\"justify\">To access a live webcast of the presentation, please visit the \u201cEvents and Presentations\u201d page within the \u201cInvestors\u201d section of the TRACON Pharmaceuticals website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5SC3oiYQgvpBHxcjShTpVnjhrHy_xGpDPWdnrt4FZhVDmoapHVkOS45PQ2Z7ZxDlCBZhQsdf1JvFP_s2YME27EPUnsTdonwfUn-UUAKIfOc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.traconpharma.com<\/a>.<\/p>\n<p align=\"left\">\n        <strong>About TRACON<\/strong>\n      <\/p>\n<p align=\"justify\">TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company\u2019s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5SC3oiYQgvpBHxcjShTpVrhYrxfrIbiyttYcOvla-Kr85FzCTcZrSoqznDv5Pr9PJpUYqarsSEgTaHdGur-2Kz1MEm7lPeMNkAny3GptwAM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.traconpharma.com<\/u><\/a>.<\/p>\n<table style=\"border-collapse: collapse;width:887px;border-collapse:collapse\">\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <u>Company Contact<\/u>:<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <u>Investor Contact<\/u>:<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Mark Wiggins<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Brian Ritchie<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Chief Business Officer<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">LifeSci Advisors LLC<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">(858) 251-3492<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">212-915-2578<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <a href=\"mailto:mwiggins@traconpharma.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mwiggins@traconpharma.com<\/a>\n          <\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <a href=\"mailto:britchie@lifesciadvisors.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">britchie@lifesciadvisors.com<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYxOSM0MDU0MTkxIzIwMTYxODg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/bb8e3f0e-2926-40f1-bc21-c496cbd85c6b\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) &#8212; TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021\u00a0at 3:10pm Eastern Time. To access a live webcast of the presentation, please visit the \u201cEvents and Presentations\u201d page within the \u201cInvestors\u201d section of the TRACON Pharmaceuticals website at www.traconpharma.com. About TRACON TRACON develops targeted therapies for cancer utilizing a capital efficient, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-453631","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) &#8212; TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021\u00a0at 3:10pm Eastern Time. To access a live webcast of the presentation, please visit the \u201cEvents and Presentations\u201d page within the \u201cInvestors\u201d section of the TRACON Pharmaceuticals website at www.traconpharma.com. About TRACON TRACON develops targeted therapies for cancer utilizing a capital efficient, &hellip; Continue reading &quot;TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-09T13:08:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYxOSM0MDU0MTkxIzIwMTYxODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference\",\"datePublished\":\"2021-03-09T13:08:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/\"},\"wordCount\":300,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjYxOSM0MDU0MTkxIzIwMTYxODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/\",\"name\":\"TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjYxOSM0MDU0MTkxIzIwMTYxODg=\",\"datePublished\":\"2021-03-09T13:08:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjYxOSM0MDU0MTkxIzIwMTYxODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjYxOSM0MDU0MTkxIzIwMTYxODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk","og_description":"SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) &#8212; TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021\u00a0at 3:10pm Eastern Time. To access a live webcast of the presentation, please visit the \u201cEvents and Presentations\u201d page within the \u201cInvestors\u201d section of the TRACON Pharmaceuticals website at www.traconpharma.com. About TRACON TRACON develops targeted therapies for cancer utilizing a capital efficient, &hellip; Continue reading \"TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-09T13:08:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYxOSM0MDU0MTkxIzIwMTYxODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference","datePublished":"2021-03-09T13:08:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/"},"wordCount":300,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYxOSM0MDU0MTkxIzIwMTYxODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/","name":"TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYxOSM0MDU0MTkxIzIwMTYxODg=","datePublished":"2021-03-09T13:08:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYxOSM0MDU0MTkxIzIwMTYxODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYxOSM0MDU0MTkxIzIwMTYxODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tracon-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=453631"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453631\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=453631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=453631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=453631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}